Medication info
Glimepiride Tablet 2 mg (Glimepiride)

Glimepiride Tablet 2 mg (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
KMS Pharmaceutical Co., Ltd.
Appearance
Green snowman-shaped tablet
Packaging
30 tablets/bottle, 500 tablets/bottle
Approval status
Active

MFDS item code 200403269 · Notified 2004.08.31 · Insurance code 654700020

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is taken orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dosage titration In patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control with an increase to 6 mg (or 8 mg). If treatment with 4 mg per day is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no precise dose-equivalence relationship between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, follow the instructions under Initial dosage. That is, start at 1 mg once daily and adjust the dose at intervals of 1 ~ 2 weeks. Consider the potency and duration of action of the previously administered medicine. 4) Dose adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur after initial successful management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up by a physician and may sometimes require hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) is above 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and start insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, monitor capillary blood glucose daily whenever possible. Insulin dosage should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. With combination therapy of this medicine and metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia with concomitant use of this medicine and metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
KMS Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It can be administered alone, and if blood sugar control is insufficient, it may also be used in combination with oral hypoglycemic agents or insulin. Additionally, when glucose control is difficult with sulfonylureas or metformin monotherapy, it can be used alongside metformin. This medication serves effectively as a treatment to assist blood sugar management in patients with type 2 diabetes.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is taken orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dosage titration In patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control with an increase to 6 mg (or 8 mg). If treatment with 4 mg per day is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no precise dose-equivalence relationship between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, follow the instructions under Initial dosage. That is, start at 1 mg once daily and adjust the dose at intervals of 1 ~ 2 weeks. Consider the potency and duration of action of the previously administered medicine. 4) Dose adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur after initial successful management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up by a physician and may sometimes require hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) is above 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and start insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, monitor capillary blood glucose daily whenever possible. Insulin dosage should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. With combination therapy of this medicine and metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia with concomitant use of this medicine and metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be administered to patients with insulin-dependent diabetes or those in a diabetic coma. Patients who have had allergic reactions to this medication, sulfonylureas, or sulfonamide medications should avoid its use. There is no prior experience with its use in patients with severe liver or kidney dysfunction; thus, transitioning to insulin therapy is advised for such cases. Women who are pregnant or may become pregnant, as well as breastfeeding women, should not take this medication. For patients with severe infections, pre- or post-surgical conditions, or severe trauma, insulin therapy is recommended. Patients with gastrointestinal disorders should be cautious, as issues with food absorption could increase the risk of hypoglycemia. This medication contains lactose and should not be given to patients with genetic metabolic disorders such as galactose intolerance. During the initial dosing, the risk of hypoglycemia is high, hence special caution is warranted, especially in elderly patients, those with poor nutritional status, and those with irregular meal patterns. Patients who consume alcohol or have impaired liver and kidney function may also have an increased risk of hypoglycemia. Furthermore, careful monitoring is necessary for those with thyroid or adrenal dysfunction, and in cases of overdose, the risk of hypoglycemia is elevated. Patients who have allergic reactions to Yellow No. 4 (Tartrazine) should use this medication cautiously. It is essential to understand the symptoms of hypoglycemia when taking this medication; if hypoglycemia occurs, sugary foods should be consumed immediately. Severe hypoglycemia may require medical treatment. Additionally, this medication lowers blood sugar levels, thus regular monitoring of blood sugar control is necessary, and if effects are insufficient, other treatment methods may need to be considered. Drug interactions should also be noted. Concurrent use with certain medications may increase or decrease the blood sugar-lowering effect; therefore, other medications must be disclosed to a physician or pharmacist. Special attention should be paid to changes in blood sugar when combined with beta-blockers, antibiotics, antifungals, and steroids. Pregnant or breastfeeding women should refrain from taking this medication; if necessary, transitioning to insulin therapy is safer. Elderly patients should be cautious regarding dosage adjustments due to common occurrences of decreased kidney function. In case of overdose, severe hypoglycemia may occur, requiring immediate medical attention, with possible emergency measures such as inducing vomiting, stomach flushing, or glucose injections. Lastly, the safety and efficacy of this medication have not been established in children, so it is advisable to avoid use in individuals under 18 years of age.

Side effects

  • Hypoglycemia
  • headache
  • severe hunger
  • nausea
  • vomiting
  • fatigue
  • sleep
  • sleep disorder
  • anxiety
  • aggression
Show 68 more
  • decreased concentration
  • decreased agility or motivation
  • depression
  • confusion
  • speech abnormalities
  • aphasia
  • visual impairment
  • tremors
  • partial paralysis
  • sensory abnormalities
  • dizziness
  • weakness
  • loss of self-control
  • transient mental confusion
  • cerebral convulsions
  • drowsiness
  • loss of consciousness
  • coma
  • shallow breathing
  • bradycardia
  • sweating
  • cold and moist skin
  • tachycardia
  • hypertension
  • palpitations
  • angina pectoris
  • deep vein thrombosis
  • blurred vision
  • fullness in the upper abdomen
  • pressure
  • abdominal pain
  • diarrhea
  • increased liver enzymes
  • liver dysfunction
  • bile secretion disorder
  • jaundice
  • hepatitis
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • erythropenia
  • granulocytopenia
  • agranulocytosis
  • pancytopenia
  • itching
  • hives
  • rash
  • shortness of breath
  • hypotension
  • shock
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • allergic vasculitis
  • photosensitivity reactions of the skin
  • decreased serum sodium concentration
  • taste disorder
  • hair loss
  • weight gain
  • dizziness
  • liver dysfunction
  • abdominal pain
  • joint pain
  • dyspepsia
  • facial swelling
  • erectile dysfunction
  • flushing
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, thus it should be stored in a sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature. Proper storage will safely preserve the medication's efficacy.

Appearance and packaging

Appearance

Green snowman-shaped tablet

Package unit

30 tablets/bottle, 500 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.